Objective-Higher triglyceride (TG) is a risk factor for incident type 2 diabetes mellitus (T2DM), but paradoxically, genetic susceptibility for higher TG has been associated with lower T2DM risk. There is also evidence that the genetic association may be modified by baseline TG. Whether such associations can be replicated and the interaction is selective for certain TG-rich lipoprotein particles remains to be explored. per mmol/L; P interaction =0.0007). In TG-adjusted analysis, large and medium but not small TG-rich lipoprotein particles were associated with higher T2DM incidence for successively lower 40-single-nucleotide polymorphism TG genetic risk score tertiles, P interaction =0.013, 0.012, and 0.620 across tertiles, respectively. Conclusions-Our results confirm the previous observations of the paradoxical associations of TG with T2DM while focusing attention on the larger TG-rich lipoprotein particle subfractions, suggesting their importance in clinical profiling of T2DM risk.
levated serum triglyceride (TG) level is an independent risk factor for type 2 diabetes mellitus (T2DM) incidence, even after controlling for body mass index (BMI) and all other conventional risk factors.
1,2 From a clinical perspective, elevated TG levels may be observed as much as 10 years before diagnosis of T2DM. 3, 4 In conventional analysis, TG is substantially confined to the chylomicron and VLDL (very low-density lipoprotein) fractions, collectively termed as TG-rich lipoprotein particles (TRLP). However, TRLPs are highly heterogeneous, and technological developments using nuclear magnetic resonance allow detection of 5 discrete TRLP subfractions, including very large, large, medium, small, and very small, as defined by lipoprotein particle diameter, 5 each of which may have distinct clinical properties. Therefore, further delineating associations between TG with T2DM according to TRLP subfractions may provide clinical insight.
Since 2007, through genome-wide association studies, about 40 independent genetic loci have been discovered for association with TG levels. 6, 7 When combined as a genetic risk score (GRS), the TG-raising alleles at these loci provide a quantitative and continuous measure of genetic susceptibility to elevated TG levels. Recently, Klimentidis et al 8 reported a significant interaction between a TG-specific weighted GRS (TG-wGRS) and baseline TG for association with T2DM risk. The authors observed that TG was more strongly associated with T2DM incidence in low compared with high TG-wGRS individuals. Klimentidis et al 8 and Li et al 9 also reported that many of the TG-associated genetic variants at or near CILP2, GCKR, NAT2, PLA2G6, CETP, and APOA1 genes were positively associated with TG but negatively associated with glycemic traits and T2DM. Meanwhile, formal Mendelian randomization analysis using TG-specific genetic instruments found no evidence of causal association between plasma TG and T2DM and instead suggested a protective effect of genetically raised TG levels on T2DM. 10, 11 In the current study, we seek to confirm and further explore these paradoxical findings by using the large, prospective population-based sample of middle-aged women from the WGHS (Women's Genome Health Study) to evaluate whether established TG-associated loci modify the association of baseline TG with the incidence of T2DM during a mean 18.6 years of follow-up. We also aimed to investigate whether the relationship between TG with T2DM risk can be refined to specific TRLP subfractions, potentially informing which biological aspects of lipid metabolism influence development of T2DM.
Materials and Methods

Study Population
Individual-level data for the WGHS are not currently publicly available, but scripts for performing the analysis described in this report will be provided on request. The study participants of the WGHS are derived from the WHS (Women's Health Study) that was designed as a placebo-controlled randomized trial evaluating the impact of low dose of aspirin and vitamin E for the primary prevention of cardiovascular disease 12, 13 among initially healthy middle age (≥45 years of age) female, healthcare professionals. Subsequent to the conclusion of the trial, the study population has been followed in observational mode. The WGHS consists of ≈72% of WHS participants with a baseline blood sample. For the current analysis, we have 23 294 participants with available genotype data and self-reported European ancestry that was also confirmed through genetics. 12 Klimentidis et al 8 performed analyses in the fasting sample, and considering this, for the current primary analyses, we have 15 813 of 21 848 participants without diabetes mellitus at baseline who also had >8 hours of fasting status, also at baseline. Secondary analyses were performed among all participants (fasting and nonfasting). Analysis in the WGHS was approved by the Institutional Review Board of Brigham and Women's Hospital, Boston.
At baseline, clinical characteristics were collected through selfreported questionnaire on age and BMI, as described previously.
14 All lipid levels, including TG and HDL (high-density lipoprotein) cholesterol (HDL-C), were enzymatically measured through Hitachi 917 analyzer (Roche Diagnostics) using baseline plasma. TGs were measured enzymatically with correction for endogenous glycerol.
Incident T2DM Ascertainment
Incident T2DM cases were initially identified by self-report using annual questionnaires that asked whether the participant had been diagnosed with diabetes mellitus since baseline. 15 Self-reported incident T2DM cases were confirmed through physician-administered telephone interviews or the questionnaires that inquired about clinical manifestations of diabetes mellitus, including diabetes mellitus medications, diagnostic diabetes mellitus testing, and disease symptoms. 16 
Measurement of TRLP Subfractions
Nuclear magnetic resonance-based measures were performed for quantifying TRLPs, as has been reported previously. 17, 18 Briefly, H-NMR (proton nuclear magnetic resonance) spectra (400 MHz) of plasma were deconvoluted with the LipoProfile IV assay (LipoScience) to resolve concentrations (nmol/L) of distinct TRLP subfractions, differentiated according to diameter, that is, particle size. For the current analysis, we considered very large (90-240 nm), large (50-89 nm), medium (37-49 nm), small (30-36 nm), and very small (24-29 nm) TRLPs. TRLP size ranged from 30 to 100 nm. The TG and cholesterol content of the combined TRLPs, designated as TRLP-TG and TRLP-cholesterol, respectively, were also determined by nuclear magnetic resonance.
Genotyping and GRS
In the WGHS, genotyping was performed with the HumanHap300 Duo array using the Infinium II assay. 19, 20 Imputation for the singlenucleotide polymorphisms (SNPs) that were not present in the genotyping array was performed using MACH (v. 1.0.16) using the 1000 genomes phase I v. 3 (March 2012) cosmopolitan reference panel. For the current analyses, we used 40-TG-associated genetic variants that have been previously reported in association with TG 6,7 as our primary genetic predictor regarding analyses because 40-TG-associated variants are similar to the 31-TG-associated genetic variants in the publication by Klimentidis et al. 8 In addition, we performed secondary analyses using recently published 127-TG-associated genetic variants. 21 Most of the SNPs were directly genotyped. The SNPs that were imputed had high imputation quality score (MACH r 2
≥0.85).
For the 40-TG-associated SNPs, effect allele frequencies, chromosomal position, and gene names have been described previously, 22 and for the 127-TG-associated SNPs, 21 this information is shown in Table  I in the online-only Data Supplement. Weighted GRSs (TG-wGRSs) were created using published effect estimates from the 40-TG (TG-wGRS 40 )-associated and 127-TG (TG-wGRS 127 )-associated genetic variants separately and scaled such that each unit reflects 10 alleles, as described previously.
22
Stastical Analysis
Cox proportional regression models were used to assess the association of TG, TRLPs, SNPs, and the TG-wGRSs with the incident T2DM. Interaction analyses were performed by additionally introducing a term of TG-associated SNPs or the TG-wGRSs×TG in the Cox models. For interaction analyses, the TG-wGRSs were used as continuous variables or as tertiles (coded as 0, 1, and 2). TG was used as a continuous variable. The basic models were adjusted with principle components (PCs; to control for European population substructure), age, and randomization to treatment in the WHS parent cohort (vitamin E and aspirin). The fully adjusted models included covariates from the basic model plus measures of HDL-C and BMI, similar to Klimentidis et al. 8 All clinical covariates were determined at baseline. For the SNP analysis, we considered a significant threshold of P ≤0.00125 (0.05/40) after Bonferroni correction for the 40 SNP tests performed. Very large and large TRLP variables were not normally distributed because the distribution of these variables were left skewed. To assess the significance of associations with these variables, we used permutation procedures to derive empirical association P values. We repeated the Cox regression over 10 000 iterations, each time resampling the TG-wGRS 40 at random without replacement to generate a null distribution of β-coefficients. The empirical P values were derived as the proportion of β-coefficients from the empirical null distribution with absolute value greater than the absolute value of the β-coefficient from the unpermuted model. Also, because many of the study participants have lower or even undetectable concentrations of very large TRLP particles, we created variable combining the very large and large TRLP particles and tested that combined variable in interaction with TG-wGRS 40 in predicting T2DM incidence. In sensitivity analyses, we generated trait residuals by regressing TG (and other TRLPs) against the TG-wGRS 40 to eliminate collinearity and used the residuals as an interactor variable with the TG-wGRS 40 to assess association with T2DM. To investigate whether interactions with the TG-wGRS 40 were consistent with the implicit assumption that the ratio of SNP effects between strata of TG was similar across all SNPs, we regressed SNP effects for incident T2DM (as β-coefficients) in the group with TG below or equal to median TG against the group with TG above median. SNPs with disproportionate influence on the regression relationship were identified using the R function "influence.measures" that flag extreme points for any of a series of regression diagnostics, including Cook D, leaveone-out analysis, covariance ratio, and leverage.
Results
Clinical and general characteristics of the study participants are shown in Table 1 . For the current analyses, there were n=15 813 with fasting status (and n=21 848 in total) female participants from the WGHS among whom 1453 experienced incident T2DM during follow-up (n=1944 incident T2DM cases in total sample). The mean follow-up duration for T2DM incidence was 18.6 (SD=5.3) years.
Associations of TG, TG-wGRS, and Incident T2DM
Although 40 SNPs have been identified through genome-wide association studies for TG, Klimentidis et al 8 performed analysis using a TG-wGRS based on 31 TG-associated SNPs because they observed that this TG-wGRS was more strongly associated with TG. However, by reviewing the literature, we found that 3 SNPs, COBL1 rs10195252, APOB rs1042034, and APOE rs439401, were not primarily or secondarily associated with TG in the most recent genome-wide association studies. 6 We therefore constructed a TG-wGRS and performed all of our primary analyses using 40-TG-associated SNPs after excluding these 3 inconsistent SNPs but including 12 additional SNPs (PIGV-NR0B2 rs12748152, LRPAP1 rs6831256, VEGFA rs998584, RSPO3 rs719726, MIR148A rs4719841, MET rs38855, AKR1C4 rs1832007, PDXDC1 rs3198697, FTO rs1121980, MPP3 rs8077889, INSR rs7248104, and PEPD rs731839). All of the included genetic variants were primarily or secondarily associated with TG at genome-wide significance. 6 The TG-wGRS 40 We observed a significant interaction of baseline TG levels and the TG-wGRS 40 (P interaction =0.002) for incident T2DM when the Cox model was adjusted for age and PCs. This interaction was also observed when the regression model was additionally adjusted for baseline BMI and HDL-C (P interaction =0.030; Table 2 ). Through residual trait analysis, we observed that the TG-wGRS 40 explained 4.99% trait variance in TG, similar to previously reported estimates. 22 When we replaced the TG with GRS-residualized TG in the analysis, the TG-wGRS 40 ×trait-residual interactions for incident T2DM remained significant (P interaction =0.005 for the basic model and P interaction =0.05 for the fully adjusted model). In the Cox model adjusted for age and PCs, we observed that TG was associated with higher incidence of T2DM in the low TG-wGRS 40 Figure I in the online-only Data Supplement). Similar interactions were observed when the regression models were additionally adjusted with BMI and HDL-C (Table 3) . Similar to the finding with the TG-wGRS 40 , we observed significant interactions of TG-wGRS 127 and TG levels in the risk of T2DM in the basic model (P interaction =0.008) and in the fully adjusted model (P interaction =0.0432; Table 2 ).
TG-Rich Lipoproteins, TG-wGRS, and T2DM Risk
In Cox models adjusted for basic covariates, total TRLP, very large, large, medium, very small TRLPs, TRLP size, Basic model was adjusted with age, PCs, vitamin E, and aspirin. Fully adjusted model was adjusted with basic model+BMI and HDL-C. Full+TG: fully adjusted model+TG. BMI indicates body mass index; HDL, high-density lipoprotein; HR, hazard ratio; PC, principle component; TG, triglyceride; TRLP, triglyceride-rich lipoprotein particle; TRLTC, TRLP-cholesterol; TRLTG: TRLP-TG; and TRLZ, mean triglyceride-rich particle size.
*P value for interaction between TG-wGRS 40 and lipid fraction. †P value for interaction between TG-wGRS 127 and lipid fraction. ‡Empirical P interaction =0.0024 after 10 000 permutations (Methods).
TRLP-TG, and TRLP-cholesterol but not small-TRLPs were significantly associated with T2DM (all P values ≤0.0001), as has been published previously in a similar WHS sample. 16 Regarding the TG-wGRS 40 , when the regression models were fully adjusted for BMI and HDL-C along with total TG at baseline, we observed significant interactions between TG-wGRS 40 and large TRLP (P interaction =0.016) and medium TRLP (P interaction =0.047) with T2DM (Table 2) . No significant interactions were observed for very large (P interaction =0.107), very small (P interaction =0.891), or small (P interaction =0.828) TRLPs. Similarly, a variable combining large and very large TRLP particles showed significant interaction with TG-wGRS 40 in the incident T2DM (P interaction =0.0035). For both the large TRLPs and the combination of large and very large TRLPs, in models adjusted with basic covariates, we also observed significant interaction using a resampling approach to derive an empirical procedure to address the skew in the TRLP distribution (P interaction, empirical =0.0024 and 0.0057, respectively). Similarly, we observed concordant interactions for the different TG-rich lipoprotein subfractions (as shown in Table 2 ). Accordingly, in fully adjusted model additionally adjusted with baseline TG, we observed a stronger association of large TRLPs with incidence of T2DM among individuals in the lower TG-wGRS 40 Table 3 ). However, the Basic model was adjusted with age, PCs, vitamin E and aspirin. Fully adjusted model was adjusted with basic model+BMI and HDL-C. Full+TG: fully adjusted model+TG. BMI indicates body mass index; GRS, genetic risk score; HDL-C, high-density lipoprotein; HR, hazard ratio; PC, principle component; TG, triglyceride; TRLP, triglyceride-rich lipoprotein particle; TRLTC, TRLP-cholesterol; TRLTG: TRLP-TG; and TRLZ, mean triglyceride-rich particle size. interactions with tertiles of TG-wGRS 40 were nonsignificant for small and very small TRLPs (P interaction =0.620) and (P interaction =0.648), respectively. We observed materially similar results when the analyses were performed in the total WGHS sample, including both fasting and nonfasting participants ( Table I in 
Justification of Using a GRS for Testing Interactions With TG
One assumption in using a GRS for gene-environment interaction studies, is that the ratio of individual SNP effects across environmental strata should be approximately similar for all SNPs. We tested this assumption by comparing SNP-T2DM association between 2 strata of TG (dichotomous variable was created based on the median value: low, ≤1.29 mmol/L, versus high, >1.29 mmol/L). In a linear model of SNP effects in the 2 strata, we observed that 4 of the SNPs (KLHL8 rs442177, APOA1 rs964184, CAPN3 rs2412710, and CILP2 rs10401969) had disproportionate influence on the regression fit (Table II in the online-only Data Supplement; Figure II in the online-only Data Supplement). We performed sensitivity analysis of TG-wGRS 40 ×TG interactions in T2DM after removing the most influential SNPs (KLHL8 rs442177, APOA1 rs964184, CAPN3 rs2412710, and CILP2 rs10401969) from the TG-wGRS 40 and observed significant interactions with TG (P interaction =0.016) for the basic model but not for the fully adjusted model (P interaction =0.27).
Pleiotropic Effects
To reduce the potential influence of known pleiotropic effects on our conclusions, we removed genetic variants from the TG-wGRS 40 However, in models additionally adjusted for baseline TG, HDL-C, and BMI, the 34-SNP TG-wGRS was negatively associated with T2DM (HR [95% CI], 0.67 [0.58-0.77] per 10-TGassociated risk alleles; P≤0.0001). Similar to the 40-SNP TG-wGRS, we observed significant interactions of the 34-SNP TG-wGRS with very large TRLPs (P interaction =0.016) and large TRLPs (P interaction =0.001) for association with T2DM outcomes (Table III in P≤0.0001). As was found for the TG-wGRS 127 , we observed significant interactions between 112-SNP TG-wGRS and TG for the T2DM outcome in the basic model (P interaction =0.021) and the fully adjusted model (P interaction =0.047).
Individual SNPs, TG, and T2DM Incidence
In SNP analyses, we observed that 5 (of 40) SNPs, including FADS1-2-3 rs174546, APOA1 rs964184, CETP rs3764261, CILP2 rs10401969, and PLA2G6 rs5756931, showed significantly negative association (P≤0.05) with T2DM incidence, but after correction for multiple testing, only APOA1 rs964184 remained statistically significant (Table 4) . Moreover, 18 of the 40 SNPs were directionally negatively associated with T2DM in models adjusted for age, PCs, BMI, and HDL. Regarding SNP×TG interactions on T2DM incidence, we observed that a significant excess (P≤0.001) of 9 (of 40) variants showed nominally significant interactions (P≤0.05), but after correction for multiple testing, none of the variants remained statistically significant (Table 4) .
Discussion
By using data from a well-powered prospective sample of initially healthy US women with homogeneous European ancestry, our study provides a compelling evidence that genetic risk for higher TG derived from a 40-SNP TG-wGRS is associated with lower T2DM risk, contrary to the positive observational associations with TG levels. Further, there was a significant interaction between the TG-wGRS 40 and TG levels for predicting incident T2DM such that individuals with lower genetic predisposition to elevated TG had relatively stronger TG-based risk of T2DM than individuals with high genetic predisposition to elevated TG. We observed similar findings when the analyses were performed using a TG-wGRS based on 127 TG-associated genetic variants. These results confirm findings from Klimentidis et al, 8 who studied a TG-wGRS based on 31 SNPs and found both reduced risk of T2DM with increased genetic risk of TG and an interaction between the TG-wGRS and TG levels for T2DM. The 40 SNPs in our TG-wGRS excluded 3 SNPs from the TG-wGRS of Klimentidis that only had weak evidence of TG association while including 12 additional SNPs with primary association for TG.
The current study also extends the previously reported discordant effects of a TG-wGRS on TG and T2DM incidence and the interaction of TG with the TG-wGRS in the study by Klimentidis et al. 8 Our investigation focuses on the interaction effects with TG to the large and medium but not small or very small TRLPs, even after adjustment with TG. Given the significant interaction of medium and large TRLPs, it may have been surprising that there was no significant interaction with the very large TRLPs (findings are summarized in the Figure) . However, ≈20 % of the sample had no detectable very large TRLPs leading to lower variability in very large TRLPs compared with the others. The combined variable of large and very large TRLP particles showed significant interaction with TG-wGRS 40 for incident T2DM and the significance was affirmed by the empirically P values.
Previously, Mora et al, 16 using the same sample, reported that large TRLPs were associated with higher risk of T2DM compared with the smaller TRLPs, which was further confirmed in 2 independent cohorts of multiethnic men and women. 24, 25 Similarly, Garvey et al, 26 reported that higher insulin resistance was associated with large but not small TRLPs. Festa et al 27 reported that larger but not smaller TRLPs were associated with increased risk of T2DM among 800 individuals of the Insulin Resistance Atherosclerosis Study who were followed up for 5 years. Although the interactions persisted in TG-adjusted analysis, the biochemical mechanism of our observed interactions may, nevertheless, be related to the larger amount of TG that is carried by larger compared with smaller TRLPs. Comparing individuals having insulin sensitivity with those with insulin-resistant phenotypes, hepatic overproduction of larger TRLPs is a key feature of dyslipoproteinemia of insulin resistance and T2DM. 28 It has been reported through in vivo lipoprotein kinetic experiments that increased larger TRLPs can change the composition of HDL particles through the action of CETP (cholesteryl ester transfer protein) and hepatic lipase, which targets TG, and this process leads to formation of small, dense HDL particles and also increased catabolism of these particles. 29 In turn, catabolism of HDL particles is associated with the formation of small dense LDL particles, which have been associated with insulin resistance and T2DM-related phenotypes. 30 It is common in GRS interaction effects analysis to draw SNP weights in constructing GRS from SNP marginal association effects. This approach assumes that the magnitude of main and interaction effects across SNPs are highly correlated, and indeed, genetic variants that show main effect association with a trait are generally good candidates for interaction effects. 31 In a previous interaction analysis with adiposity, we have shown that the assumption was largely valid for the TG-wGRS 40 in relation to TG as the outcome across normal compared with overweight/obese strata. 22 By adopting that same approach, we demonstrate that the results here were largely valid also for interaction with TG in predicting T2DM, although the assumption of proportionality was challenged for 4 of the genetic variants (KLHL8 rs442177, APOA1 rs964184, CAPN3 rs2412710, and CILP2 rs10401969). Excluding these SNPs, the interaction of the GRS and TG-wGRS 40 for T2DM remained significant.
The biological and pathophysiological mechanisms through which higher TG-wGRSs were protective for the risk of T2DM, after adjusting with baseline TG and HDL-C, are not clear. The effects of the TG-associated genetic variants on T2DM may reflect their role in hepatic de novo lipogenesis 32 through which they might regulate glucose uptake and glycolysis and may subsequently increase plasma TG levels. 33 A potential explanation of the discordant effects of TG and T2DM is that higher glucose utilization and glycolytic flux leads to downregulation of glucose-6-phosphatase and upregulation of GCK (glucokinase), phosphofructokinase, and fatty acid synthases. These changes lead to higher glycogen synthesis, increased concentration of malonyl CoA, and production of larger TRLP subfractions. 34 Our observation that TG-wGRSs positively associate with TG but with lower risk to T2DM is consistent with this hypothesis.
Our study has many strengths, including a large number of incident T2DM cases, the homogenous study sample, a comprehensive collection of TG-associated genetic variants, longitudinal study design, and complete profiles of TRLP subfractions and standard lipids. The long follow-up duration for incident T2DM also reduces the likelihood of reverse causation. Our study has several limitations including that our sample was based on European ancestry female participants only; the generalizability of the current findings still needs to be established by testing among ancestrally diverse populations. TG, HDL-C, and LDL particles are highly correlated lipid fractions, and it is difficult to distinguish the specific effects of one lipid fraction versus another. To limit such potential pleiotropic effects, TG-wGRS and T2DM incidence analyses were additionally adjusted with HDL-C and LDLcholesterol, and the results were materially similar. However, the findings from the study by Klimentidis et al 8 were based on both male and female participants and were similar to our findings suggesting that they are independent of sex.
In summary, our findings provide novel information understanding the complex relationship between TG and T2DM by focusing this relationship on the large TRLP component of TG. At the clinical level, the gene-based relationship between TG-and T2DM-related traits was opposite to the observational relationship, suggesting a complex gene regulation and cardiometabolic interplay between TG-and T2DM-related traits. One expects that the mechanisms underlying our associations most likely occur in tissues where lipids and T2DM-related biomolecules are synthesized and stored. Our findings thus suggest future studies using systematic biological approaches using liver, muscle, and adipose tissues are warranted to help further understand the causal links between lipids, glycemic traits, and their consequences to T2DM risk.
accuracy of the data analysis. All authors critically revised the paper for important intellectual content and approved the final version.
